Neuroprotection by gonadal steroid hormones in acute brain damage requires cooperation with astroglia and microglia

J Steroid Biochem Mol Biol. 2013 Sep:137:71-81. doi: 10.1016/j.jsbmb.2012.11.006. Epub 2012 Nov 26.

Abstract

The neuroactive steroids 17β-estradiol and progesterone control a broad spectrum of neural functions. Besides their roles in the regulation of classical neuroendocrine loops, they strongly influence motor and cognitive systems, behavior, and modulate brain performance at almost every level. Such a statement is underpinned by the widespread and lifelong expression pattern of all types of classical and non-classical estrogen and progesterone receptors in the CNS. The life-sustaining power of neurosteroids for tattered or seriously damaged neurons aroused interest in the scientific community in the past years to study their ability for therapeutic use under neuropathological challenges. Documented by excellent studies either performed in vitro or in adequate animal models mimicking acute toxic or chronic neurodegenerative brain disorders, both hormones revealed a high potency to protect neurons from damage and saved neural systems from collapse. Unfortunately, neurons, astroglia, microglia, and oligodendrocytes are comparably target cells for both steroid hormones. This hampers the precise assignment and understanding of neuroprotective cellular mechanisms activated by both steroids. In this article, we strive for a better comprehension of the mutual reaction between these steroid hormones and the two major glial cell types involved in the maintenance of brain homeostasis, astroglia and microglia, during acute traumatic brain injuries such as stroke and hypoxia. In particular, we attempt to summarize steroid-activated cellular signaling pathways and molecular responses in these cells and their contribution to dampening neuroinflammation and neural destruction. This article is part of a Special Issue entitled 'CSR 2013'.

Keywords: AD; AQP; ATP; Alzheimer's disease; Astroglia; BBB; BSA; CNS; Ca(2+)/calmodulin-dependent protein kinases; CaMK; EAE; ER; ERK; Estrogen; G-protein coupled receptor 30; GFAP; GLAST; GLT-1; GPR30; ICI; ICI 182,780; IGF; IL; Ko; MAPK; MHC; MMP; MNAR; Microglia; NF-κB; PELP1; PI3K; PKA; PKC; Progesterone; RCEs; ROS; SERM; Src; TGF-β; TNF-α; VEGF; adenosine triphosphate; aquaporin; blood–brain barrier; bovine serum albumin; central nervous system; estrogen receptor; experimental autoimmune encephalomyelitis; extracellular signal-related kinase; glial fibrillary acidic protein; glutamate transporter-1; gutamate–aspartate transporter; iNOS; inducible nitric oxide synthase; insulin-like growth factor-1; interleukin; knockout; major histocompatibility complex; matrix metalloproteinase; mitogen-activated protein kinase; modulator of nongenomic activity of ER; nuclear factor-kappa B; phosphatidylinositol 3-kinases; proline, glutamate and leucine rich protein1; protein kinase A; protein kinase C; radical oxygen species; respiratory chain enzymes; sarcoma; selective estrogen receptor modulator; siRNA; small interfering RNA; tMCAO; transforming growth factor-beta; transient middle cerebral artery occlusion; tumor necrosis factor-alpha; vascular endothelial growth factor.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Astrocytes / pathology*
  • Brain Injuries / pathology
  • Brain Injuries / therapy*
  • Gonadal Steroid Hormones / pharmacology*
  • Humans
  • Microglia / pathology*
  • Neuroprotective Agents / pharmacology*

Substances

  • Gonadal Steroid Hormones
  • Neuroprotective Agents